VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

AdC68- rabies virus glycoprotein
Vaccine Information
  • Vaccine Ontology ID: VO_0004630
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • G gene engineering:
    • Type: Recombinant vector construction
    • Description: A plasmid vector, termed pSG5rab.gp, that expresses the rabies virus glycoprotein under the control of an SV40 early promoter (Xiang et al., 1994).
    • Detailed Gene Information: Click Here.
  • Vector: (Xiang et al., 2014)
  • Preparation: Chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein (Xiang et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Monkey Response

  • Vaccination Protocol: An AdC vector control was used at 1011 vp. A commercially available human diploid cell rabies vaccine (HDCV), used intramuscularly at the recommended dose for pre-exposure vaccination, was included. The AdC vector vaccine was only given once, and the HDCV was given three times on days −41, −27 and −20 in relation to the AdC vaccine (Xiang et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Animals were challenged at 18 weeks after the last vaccine dose with ~106.4 (MICLD)50/ml as calculated via the Spearman–Kaerber method, of a virulent street strain of canine rabies virus (Xiang et al., 2014).
  • Efficacy: The immunization resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model (Xiang et al., 2014).
References
Xiang et al., 1994: Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994; 199(1); 132-140. [PubMed: 8116236].
Xiang et al., 2014: Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology. 2014; 450-451; 243-249. [PubMed: 24503087].